ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Stemline Therapeutics, Inc." (STML) Report Updated: Oct 19, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"Stemline Therapeutics, Inc." (STML)

Rating: Sell Volatility: Moderate
Total Grade: D Industry: Biotechnology
Competitors: RGEN, CBPO, CBMG, MACK

Stock Analysis

Rating: Monthly View

A
B
C
D
F
October November December January February March April May June July August September

Rating: Weekly View

This Week: D down no change
Last Week: D same no change
Two Weeks Ago: D up no change
service keys

"Stemline Therapeutics, Inc."© quotemedia

Company Profile

Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary therapeutics for cancer stem cells and bulk tumors. It develops SL-401, a biologic-drug conjugate, which has completed Phase I/II clinical trials for advanced hematologic cancers; and SL-701, a vaccine that has completed two Phase I/II clinical trials for multi-epitope brain cancer. The company was founded in 2003 and is based in New York, New York.

Recent News: "Stemline Therapeutics, Inc."